Immunohistochemical Expression of Galectin-9 in Oral Squamous Cell Carcinoma
Galectin 9 (Gal9) has a diversified role in cancer pathogenesis. It induces aggregation of certain cell types and prevents metastasis. Recent evidence revealed its pivotal role in immune regulation. Limited literature is available on the expression of Gal9 in OSCC, and no data is available on its correlation with chewable tobacco products, which is the most potential risk factor of OSCC. Therefore, this research aims to reveal the expressions of Gal9 on OSCC tissue samples and identify its association with anatomical sites and risk factors, which has never been done before. This cross-sectional study was conducted on 126 OSCC diagnosed cases. Consent and demographic details were obtained before the selection of cases. The obtained data were analyzed statistically via SPSS version 20. Gal9 was positively expressed in the cytoplasm of (89; 70.6%) OSCC cases. Both quantitative and qualitative analyses of Gal9 displayed a statistically significant correlation of Gal9 with tobacco consuming habits (p-value 0.04), 51-60 years age group (p-value 0.013), anatomical location of buccal mucosa (p-value 0.03), with stage III cancer (p-value 0.009), and degree of tumor differentiation (p-value 0.035). Our results indicate statistically significant relevance of Gal9 with tumor grades and stages that indicate severe tumor progression and dismal prognosis. For the first time in the literature, we have revealed the significant relationship of Gal9 with chewable and smoking tobacco products and Naswar. These products hold great potential in the carcinogenesis of OSCC, which is the most prevalent tumor in our region. This merits additional research in this domain to draw a definitive diagnosis.
Keywords: Galectin-9, carcinoma, squamous cell, immunotherapy.
JOHNSON D.E., BURTNESS B., LEEMANS C.R. et al. Head and Neck Squamous Cell Carcinoma. Nature Reviews Disease Primers, 2020, 6(1): article ID 92.
D'CRUZ A.K., R. VAISH & DHAR H.J.O.O. Oral Cancers: Current Status. Oral Oncology, 2018, 87: 64–69. https://doi.org/10.1016/j.oraloncology.2018.10.013
BRAY F., Ferlay, J., Soerjomataram, I., et al. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: a Cancer Journal for Clinicians, 2018, 68(6): 394-424.
SMITH C.J., et al. Categorizing the Characteristics of Human Carcinogens: A Need for Specificity. Archives of Toxicology, 2021, 95(8): 2883-2889.
FOUAD Y.A. & AANEI C. Revisiting the Hallmarks of Cancer. American Journal of Cancer Research, 2017, 7(5): 1016-1036.
GONZALEZ H., HAGERLING C. & WERB Z. Roles of the Immune System in Cancer: From Tumor Initiation to Metastatic Progression. Genes & Development, 2018, 32(19-20): 1267-1284.
MESSERSCHMIDT J.L., PRENDERGAST G.C. & MESSERSCHMIDT G.L. How Cancers Escape Immune Destruction and Mechanisms of Action for the New Significantly Active Immune Therapies: Helping Nonimmunologists Decipher Recent Advances. Oncologist, 2016, 21(2): 233-43.
PERRI, F., IONNA, F., LONGO, F., et al. Immune Response against Head and Neck Cancer: Biological Mechanisms and Implication on Therapy. Translational Oncology, 2019, 13(2): 262–274. https://doi.org/10.1016/j.tranon.2019.11.008
JANSSEN, L.M.E., RAMSAY, E. E., LOGSDON, C. D., & OVERWIJK, W. W. The immune system in cancer metastasis: friend or foe? Journal for Immunotherapy of Cancer, 2017, 5(1), 79. https://doi.org/10.1186/s40425-017-0283-9
KANDEL, S., et al. The TIM3/Gal9 Signaling Pathway: An Emerging Target For Cancer Immunotherapy. Cancer Letters, 2021, 510: 67-78.
ZHANG, C.-X., et al. Galectin-9 Promotes a Suppressive Microenvironment in Human Cancer by Enhancing STING Degradation. Oncogenesis, 2020, 9(7): 65.
CHEN, P. et al. Galectin-9-based immune risk score model helps to predict relapse in stage I-III small cell lung cancer. Journal for ImmunoTherapy of Cancer, 2020, 8(2): e001391
YASINSKA, I. M., SAKHNEVYCH, S. S., PAVLOVA, L., et al. The Tim-3-Galectin-9 pathway and its regulatory mechanisms in human breast cancer. Frontiers in Immunology, 2019, 10: 1594. https://doi.org/10.3389/fimmu.2019.01594
YANG, R., et al. Galectin-9 interacts with pd-1 and tim-3 to regulate t cell death and is a target for cancer immunotherapy. Nature Communications, 2021, 12(1): 832.
LABRIE, M. et al. Tissue and Plasma Levels of Galectins in Patients with High Grade Serous Ovarian Carcinoma as New Predictive Biomarkers. Scientific Reports, 2017, 7(1): 13244.
ZHOU X., SUN L., JING D., et al. Galectin-9 Expression Predicts Favorable Clinical Outcome In Solid Tumors: A Systematic Review And Meta-Analysis. Frontiers in Physiology, 2018, 9: 452.
WANG, K., et al. Prognostic Role of High Gal-9 Expression in Solid Tumours: A Meta-Analysis. Cellular Physiology and Biochemistry, 2018, 45(3): 993-1002.
RANJBAR Z., GOLFESHAN F., KHADEMI B. et al. Serum Levels of Galectin-9 in Patients with Oral Squamous Cell Carcinoma. Eurasian Journal of Biosciences, 2020, 14: 141-147.
PU, F., et al. TIM-3 Expression and its Association with Overall Survival in Primary Osteosarcoma. Oncology Letters, 2019, 18(5): 5294-5300.
QUEROL CANO, L., et al. Intracellular Galectin-9 Controls Dendritic Cell Function by Maintaining Plasma Membrane Rigidity. Iscience, 2019, 22: 240-255.
GILBERT S. G., KRAUTTER F., COOPER D., et al. CASTLE: Cell Adhesion With Supervised Training And Learning Environment. Journal of Physics D: Applied Physics, 2020, 53(42): 424002
WDOWIAK, K., GALLEGO-COLON, E., FRANCUZ, T., et al. Increased serum levels of Galectin-9 in patients with chronic lymphocytic leukemia. Oncology Letters, 2019, 17(1): 1019–1029. https://doi.org/10.3892/ol.2018.9656
MOAR, P. & TANDON R. Galectin-9 As A Biomarker of Disease Severity. Cellular Immunology, 2021, 361: 104287.
GONÇALVES SILVA I., YASINSKA I. M., SAKHNEVYCH S. S., et al. The Tim-3-galectin-9 Secretory Pathway is Involved in the Immune Escape of Human Acute Myeloid Leukemia Cells. EBioMedicine, 2017, 22: 44–57. https://doi.org/10.1016/j.ebiom.2017.07.0.
CURLEY J., CONAWAY M. R., CHINN Z. et al. Looking Past PD-L1: Expression of Immune Checkpoint TIM-3 and its Ligand Galectin-9 in Cervical and Vulvar Squamous Neoplasia. Modern Pathology, 2020, 33(6): 1182-1192.
THIJSSEN, V.L., et al. Galectin Expression In Cancer Diagnosis and Prognosis: A Systematic Review. Biochimica Et Biophysica Acta (BBA) - Reviews On Cancer, 2015, 1855(2): 235-247.
ARRIOLA A.G.P., et al. PD-L1 Expression Reveals Significant Association with Squamous Differentiation in Upper Tract Urothelial Carcinoma. American Journal of Clinical Pathology, 2019, 151(6): 561-573.
- There are currently no refbacks.